Field Trip Stock Could Climb 300% In One Year
It was a big week for this Toronto company!
Last week, HC WainWright gave Field Trip Health (FTRP) a Buy rating, predicting that it will increase from $4.50 to $20 per share in just one year!
The firm noted that Field Trip’s propriety psilocybin analog, FT-104 could soon have some of the strongest intellectual property protection in the sector.
Since the analysis, the company has opened Europe’s first psychedelic therapy healthcare facility in Amsterdam, expanding its network of clinics to six facilities.
Then on Thursday, Field Trip announced that its preparing for Phase I clinical trials, which will commence early next year, to investigate FT-104 in treating post-partum depression and treatment resistant depression.